canyon landscape

A Phase 0 /II Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection

In the proposed trial, patients will be administered ribociclib+everolimus prior to surgical resection of their tumor. Recurrent GBM patients will be randomized into one of the three time-interval cohorts for the first two dose levels.

In the lead-in dose escalation study, the first six subjects (lead-in) will receive ribociclib 400 mg and everolimus 2.5 mg orally-administered in 5 daily doses with the last dose. If one or less patient experiences DLT among the 6 patients, this regimen with ribociclib 400 mg and everolimus 2.5mg will be considered safe and we will continue with the dose escalation phase of the study up to Level 3.

Four dose escalation levels:

  • Level 0: ribociclib 400mg and everolimus 2.5
  • Level 1: ribociclib 600mg and everolimus 2.5mg
  • Level 2: ribociclib 600mg and everolimus 5mg
  • Level 3: ribociclib 600mg and everolimus 10mg
Open and enrolling subjects.
Phoenix, Arizona
Total Participants
Primary Sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Additional Sponsor(s)
Ivy Brain Tumor Center
Barrow Neurological Institute